"This was a pivotal trial in establishing the safety and efficacy of tenecteplase as an alternative to alteplase in the thrombolytic treatment of acute ischemic stroke within 4.5 hours in Asian ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase seems to ...

Please provide your email address to receive an email when new articles are posted on . Reteplase was superior to alteplase at reducing disability after acute ischemic stroke. Mortality was similar ...

Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with ...

Please provide your email address to receive an email when new articles are posted on . Tenecteplase was noninferior to alteplase for acute ischemic stroke when given within 4.5 hours of symptom onset ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Intravenous alteplase is beneficial for patients who present with an acute ischemic stroke and salvageable brain tissue on imaging—with or without a large-vessel occlusion (LVO)—up to 24 hours after ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...

MONDAY, March 24, 2025 (HealthDay News) -- For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes, according to ...